Acknowledging Caronia: FDA Takes The First Step To Rethinking Off-Label Policy
This article was originally published in RPM Report
Executive Summary
FDA has gotten past the denial phase and now is listening to ideas on how to balance the need to preserve the integrity of the regulatory process with evolving interpretations of the First Amendment as it applies to commercial speech. That is slow but important progress – but towards what goal?
You may also be interested in...
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
Agency grants two citizen petitions from a coalition of pharma companies requesting greater clarity from FDA, but whether the forthcoming guidances will satisfy industry remains an open question.
Endo Lidoderm Settlements: “Golden Goose” Hatches Strong Case
Off-label promotion prosecutions are supposed to be much tougher in the post-Caronia period. However, it is not too hard for the government to make a compelling case when a marketing manager calls one off-label use the “golden goose” for a product line.
FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts
FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.